Uncategorized
VIDEO: CorneaGen to use $37 million financing to advance Corneal Cell Therapy
SAN FRANCISCO — At the Ophthalmology Innovation Summit preceding the American Academy of Ophthalmology annual meeting, Monty Montoya, CEO of CorneaGen, discusses the company’s plans to use the recently announced Series B round of financing to develop Cornea Cell Therapy for treatment of endothelial diseases.